Your Health, We Care
1. Elevated liver enzymes and drug-induced liver injury.
2. Gastrointestinal disorders.
3. Embryo-fetal toxicity.
4. Arterial thromboembolic events.
5. Bleeding risk.
6. Gastrointestinal perforation.
7. Nephrotic-range proteinuria.
FDA，2024.10
In 2019, nintedanib became the first therapy approved by the FDA to slow the rat···【more】
Release date：2026-02-03Recommended：36
